UNASSIGNED:这项研究的目的是探讨P300成分与酒精使用障碍(AUD)的临床特征和药物治疗功效的关联。
未经评估:招募了151名AUD患者和96名健康对照者,并评估了抑郁症状。焦虑,睡眠,和认知功能通过酒精使用障碍识别测试(AUDIT),9项患者健康问卷(PHQ-9),7项广义焦虑症量表(GAD-7),匹兹堡睡眠质量指数(PSQI)数字符号替换测试(DSST),和事件相关电位P300,这是平均头皮脑电图反应之一,时间锁定到特定事件。在AUD组中,101名患者完成了为期8周的药物治疗,并在干预后对上述数据进行了评估。
未经评估:1.在基线,AUD患者的AUDIT评分较高,PHQ-9,GAD-7,PSQI,和P300延迟在Cz,Pz,和Fz和较低的DSST分数和较小的P300振幅在Fz,Cz,和Pz与对照组相比。P300成分与酒精剂量和AUDIT评分显著相关,PHQ-9,GAD-7,PSQI,和DSST。2.治疗8周后,P300成分有显著变化;酒精剂量;和AUDIT评分,PHQ-9,GAD-7,PSQI,和DSST。基线处的变量,包括Fz处的P300振幅,Cz,和Pz;Fz和Pz的潜伏期;酒精剂量;以及PHQ-9、GAD-7、PSQI的评分,和DSST,与AUDIT评分降低率的变化显著相关。然而,Fz处的P300振幅,Cz,治疗8周后,AUD患者的Pz仍明显短于健康对照(HCs),和Fz的P300延迟,Cz,Pz明显长于HC。3.当验证的受试者工作特征曲线下面积(AUC)超过0.80时,基线变量包括Cz和Pz处的振幅,酒精剂量,PSQI评分可以预测AUDIT评分降低率的变化。
未经评估:Fz处的P300振幅和延迟,Cz,和Pz可作为评估AUD临床特征和严重程度的生物学标志物。Cz和Pz处的P300振幅,睡眠状态,基线认知功能可以预测AUD患者药物治疗的疗效。
UNASSIGNED: The purpose of this study is to explore the association of P300 components with clinical characteristics and efficacy of pharmacotherapy in alcohol use disorder (AUD).
UNASSIGNED: One hundred fifty-one AUD patients and 96 healthy controls were recruited and evaluated for the symptoms of depression, anxiety, sleep, and cognitive function by the Alcohol Use Disorders Identification Test (AUDIT), the 9-item Patient Health Questionnaire (PHQ-9), the 7-item Generalized Anxiety Disorder scale (GAD-7), the Pittsburgh Sleep Quality Index (PSQI), Digit Symbol Substitution test (DSST), and event-related potential P300, which is one of the averaged scalp electroencephalography responses time-locked to specific events. Among the AUD group, 101 patients finished an 8-week pharmacotherapy and were evaluated for the above data at post-intervention.
UNASSIGNED: 1. At baseline, AUD patients had higher scores of AUDIT, PHQ-9, GAD-7, PSQI, and P300 latency at Cz, Pz, and Fz and lower DSST score and smaller P300 amplitudes at Fz, Cz, and Pz compared with controls. P300 components correlated significantly with alcohol dose and score of AUDIT, PHQ-9, GAD-7, PSQI, and DSST. 2. After 8 weeks\' treatment, there were significant changes for the P300 components; alcohol dose; and score of AUDIT, PHQ-9, GAD-7, PSQI, and DSST. Variables at baseline, including P300 amplitudes at Fz, Cz, and Pz; latency of Fz and Pz; alcohol dose; and scores of PHQ-9, GAD-7, PSQI, and DSST, were significantly associated with changes of reduction rate of AUDIT scores. However, P300 amplitudes at Fz, Cz, and Pz in AUD patients after 8-week treatment were still significantly shorter than healthy controls (HCs), and P300 latencies at Fz, Cz, and Pz were significantly longer than HCs. 3. When validated area under the receiver operating characteristic curve (AUC) was over 0.80, the baseline variables including amplitudes at Cz and Pz, alcohol dose, and scores of PSQI could predict the changes of reduction rate of AUDIT score.
UNASSIGNED: P300 amplitudes and latencies at Fz, Cz, and Pz could be used as biological markers for evaluating the clinical characters and severity of AUD. P300 amplitudes at Cz and Pz, sleep condition, and cognitive function at baseline could predict the efficacy of pharmacotherapy for AUD patients.